CA
NZ
UK
AU
IND
US
Trading at barely more than a penny and carrying aMarket Valuein the hundreds of thousands of dollars, CERo Therapeutics Holdings, Inc. (OTC:CERO) sits among the most speculative names in cell therapy. The company has been trading over the counter after moving off the Nasdaq, …
The ticker CFRXQ tells much of the story before a single financial statement is opened. The trailing 'Q' is the market's shorthand for a company in bankruptcy, and ContraFect Corporation (OTC:CFRXQ) earned it the hard way.
Clinical-stage neurology names tend to trade on regulatory signposts rather than day-to-day price action, and Cognition Therapeutics fits that mold. The Nasdaq-listed company has spent 2026 sharpening the regulatory path for its lead drug candidate, even as its shares hover near the psychologically important …
Not every ticker in a healthcare-and-technology screen actually belongs to a drug developer or a software firm. Circle8 Group, Inc. (NASDAQ: CIRC) is a reminder of that: despite serving technology and finance clients, the company is a staffing and workforce-solutions provider, not a health …
Among the smallest names in the gene-therapy landscape, Calidi Biotherapeutics, Inc. (NYSE American: CLDI) commands attention less for its size than for the ambition of its science. With a marketCapitalizationof only a few million dollars and shares near $1.36 following a mid-year reverse split, …
CollPlant Biotechnologies Ltd (NASDAQ:CLGN) is a case study in promising science meeting hard commercial reality. The Israeli regenerative-medicine company builds products from plant-derived recombinant human collagen (rhCollagen), but through 2026 it has been cutting costs, exploring strategic alternatives and raising small amounts of capital.
● Clene sits at one of the more closely followed inflection points in neurodegeneration research, where a small-cap developer is trying to convert years of biomarker data into an actual regulatory filing.
On a percentage basis, a jump from $0.0001 to $0.0002 looks explosive, a clean 100% gain. In practice it is a single sub-penny tick in a stock that its own company pulled from public markets. That is the situation confronting Biostax Corp. (OTC:BTAX), a …
Few companies embodied the early promise of prescription digital therapeutics as vividly as Better Therapeutics, Inc (OTC:BTTX), and few have fallen as far. Once a Nasdaq-listed developer of software-based treatments for chronic disease, Better Therapeutics now trades as a dormant sub-penny relic.
The ticker tells much of the story before any analysis begins. Baudax Bio, Inc (OTC:BXRXQ) now trades under a symbol whose trailing Q is the market's shorthand for a company in, or associated with,Bankruptcyproceedings. Quoted at a fraction of a cent with aMarket Valuemeasured …
Please wait processing your request...